CRIS Current Research Information System

PISCAGLIA, FABIO
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
AS - Asia 26.438
NA - Nord America 26.434
EU - Europa 17.125
SA - Sud America 1.692
AF - Africa 1.354
OC - Oceania 52
Continente sconosciuto - Info sul continente non disponibili 11
Totale 73.106
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 25.984
VN - Vietnam 7.559
SG - Singapore 6.622
CN - Cina 6.066
IT - Italia 3.960
GB - Regno Unito 3.391
DE - Germania 2.138
HK - Hong Kong 1.759
SE - Svezia 1.611
BR - Brasile 1.200
FR - Francia 1.189
IN - India 1.048
BD - Bangladesh 999
RU - Federazione Russa 873
NL - Olanda 790
IE - Irlanda 651
UA - Ucraina 617
KR - Corea 564
FI - Finlandia 489
JP - Giappone 457
ZA - Sudafrica 400
TG - Togo 307
CH - Svizzera 261
CI - Costa d'Avorio 248
EE - Estonia 237
CA - Canada 227
AR - Argentina 200
PH - Filippine 190
BG - Bulgaria 174
TH - Thailandia 152
JO - Giordania 135
SC - Seychelles 132
ID - Indonesia 131
MX - Messico 131
AT - Austria 128
IQ - Iraq 112
PK - Pakistan 111
BE - Belgio 108
PL - Polonia 95
TW - Taiwan 95
TR - Turchia 90
NG - Nigeria 86
HR - Croazia 83
ES - Italia 82
EC - Ecuador 74
CL - Cile 54
CO - Colombia 46
EG - Egitto 44
IR - Iran 43
AU - Australia 42
GR - Grecia 42
SA - Arabia Saudita 42
UZ - Uzbekistan 39
PY - Paraguay 35
MA - Marocco 33
PE - Perù 32
MY - Malesia 31
RO - Romania 30
CZ - Repubblica Ceca 29
LT - Lituania 28
VE - Venezuela 26
IL - Israele 23
LB - Libano 21
AE - Emirati Arabi Uniti 20
DZ - Algeria 20
KE - Kenya 18
CR - Costa Rica 17
JM - Giamaica 17
UY - Uruguay 17
PT - Portogallo 16
OM - Oman 15
AZ - Azerbaigian 14
TN - Tunisia 14
RS - Serbia 13
ET - Etiopia 12
NP - Nepal 12
PS - Palestinian Territory 12
KZ - Kazakistan 11
MD - Moldavia 11
HU - Ungheria 10
HN - Honduras 9
KG - Kirghizistan 9
NO - Norvegia 9
PR - Porto Rico 9
AL - Albania 8
BA - Bosnia-Erzegovina 8
DO - Repubblica Dominicana 8
EU - Europa 8
LV - Lettonia 8
SK - Slovacchia (Repubblica Slovacca) 8
BH - Bahrain 7
BO - Bolivia 7
DK - Danimarca 7
MM - Myanmar 7
BY - Bielorussia 6
GE - Georgia 6
LK - Sri Lanka 6
NZ - Nuova Zelanda 6
SV - El Salvador 6
AO - Angola 5
Totale 72.992
Salva come PNG Salva come JPEG
Città #
Singapore 4.557
Ashburn 2.900
Southend 2.893
Fairfield 2.464
Ho Chi Minh City 1.745
Chandler 1.683
Hong Kong 1.623
San Jose 1.599
Hanoi 1.500
Dong Ket 1.102
Hefei 1.071
Woodbridge 1.060
Santa Clara 1.044
Seattle 1.017
Houston 1.000
Wilmington 951
Bologna 802
Cambridge 794
Princeton 754
Boardman 674
Beijing 668
Dublin 646
Ann Arbor 626
Lauterbourg 510
New York 491
Seoul 471
Los Angeles 465
Council Bluffs 429
Helsinki 382
Tokyo 375
Jacksonville 370
Dallas 335
Lomé 307
Westminster 298
Nanjing 296
Milan 292
Buffalo 268
Da Nang 263
Haiphong 252
Padova 252
Abidjan 248
Berlin 233
Munich 231
Bern 218
Rome 198
Frankfurt am Main 196
São Paulo 183
Sofia 169
Redondo Beach 162
Jinan 161
Saint Petersburg 158
Guangzhou 147
Turin 141
San Diego 139
Amman 133
Shenyang 133
Amsterdam 132
Shanghai 132
Chicago 111
Changsha 109
Florence 108
Medford 102
Nanchang 102
Tianjin 101
Bengaluru 98
Johannesburg 98
Brussels 96
Hải Dương 95
Hebei 91
Dearborn 87
The Dalles 87
London 84
Orem 82
Vienna 82
Nuremberg 81
Phoenix 81
Abeokuta 73
Des Moines 73
Falkenstein 71
Mülheim 71
Zhengzhou 67
Biên Hòa 65
Montreal 65
Naples 65
Redmond 63
Wuhan 63
Can Tho 61
Jakarta 61
Lappeenranta 61
Toronto 60
Warsaw 59
Bangkok 58
Brooklyn 57
Bremen 56
Thái Nguyên 56
Olalla 55
Mexico City 54
Atlanta 53
Hangzhou 53
Lahore 53
Totale 45.511
Salva come PNG Salva come JPEG
Nome #
Lenvatinib versus sorafenib in first-line treatment of patients with unresectable hepatocellular carcinoma: a randomised phase 3 non-inferiority trial 405
Molecular Adsorbent Recirculating System (MARS) application in liver failure: Clinical and hemodepurative results in 22 patients 404
Accuracy of spleen stiffness measurement for the diagnosis of clinically significant portal hypertension in patients with compensated advanced chronic liver disease: a systematic review and individual patient data meta-analysis 333
EFSUMB Guidelines on Interventional Ultrasound (INVUS), Part VI - Ultrasound-guided vascular interventions 333
Clinical trial: peg-interferon alfa-2b and ribavirin for the treatment of genotype-1 hepatitis C recurrence after liver transplantation 328
Guidelines and good clinical practice recommendations for Contrast Enhanced Ultrasound (CEUS) in the liver - update 2012: A WFUMB-EFSUMB initiative in cooperation with representatives of AFSUMB, AIUM, ASUM, FLAUS and ICUS. 315
Efficacy of radioembolization according to tumor morphology and portal vein thrombosis inintermediate-advanced hepatocellular carcinoma 315
Monofocal hepatocellular carcinoma: How much does size matter? 295
Laser ablation is superior to TACE in large-sized hepatocellular carcinoma: A pilot case-control study 288
Differences in liver stiffness values obtained with new ultrasound elastography machines and Fibroscan: A comparative study 287
Focal nodular hyperplasia: New findings at Doppler ultrasonography 272
Ablation for hepatocellular carcinoma: beyond the standard indications 269
Accuracy of VirtualTouch Acoustic Radiation Force Impulse (ARFI) imaging for the diagnosis of cirrhosis during liver ultrasonography 265
Imaging-based diagnosis of benign lesions and pseudolesions in the cirrhotic liver 264
A phase I study of continuous hepatic arterial infusion of Irinotecan in patients with locally advanced hepatocellular carcinoma. 262
Clinical Impact and Safety of Anticoagulants for Portal Vein Thrombosis in Cirrhosis 261
Beneficial prognostic effects of aspirin in patients receiving sorafenib for hepatocellular carcinoma: A tale of multiple confounders 257
Acute systemic, splanchnic and renal haemodynamic changes induced by molecular adsorbent recirculating system (MARS) treatment in patients with end-stage cirrhosis. 254
A new priority policy for patients with hepatocellular carcinoma awaiting liver transplantation within the model for end-stage liver disease system. 254
Evaluation of the impact of transient interruption of antiangiogenic treatment using ultrasound-based techniques in a murine model of hepatocellular carcinoma 254
The EFSUMB guidelines and recommendations for the clinical practice of contrast-enhanced ultrasound (CEUS) in Non-Hepatic Applications: Update 2017 (Long Version) 247
Ablazione percutanea ecoguidata mediante radiofrequenza di piccoli noduli di HCC: fattori correlati all'esito clinico e alla recidiva di malattia 245
A meta-analysis of single HCV-untreated arm of studies evaluating outcomes after curative treatments of HCV-related hepatocellular carcinoma 244
MiR-494 induces metabolic changes through G6pc targeting and modulates sorafenib response in hepatocellular carcinoma 243
Pattern of macrovascular invasion in hepatocellular carcinoma 242
Adherence to AASLD guidelines for the treatment of hepatocellular carcinoma in clinical practice: experience of the Bologna Liver Oncology Group. 240
MiR-30e-3p influences tumor phenotype through MDM2/TP53 axis and predicts sorafenib resistance in hepatocellular carcinoma 236
Recalibrating survival prediction among patients receiving trans‐arterial chemoembolization for hepatocellular carcinoma 235
Characterization of primary and recurrent nodules in liver cirrhosis using contrast-enhanced ultrasound: which vascular criteria should be adopted? 234
Aflatoxin B1 DNA-Adducts in Hepatocellular Carcinoma from a Low Exposure Area 233
Landscape of alcohol-related hepatocellular carcinoma in the last 15 years highlights the need to expand surveillance programs 233
Use of perfusional angiosonography in liver transplantation and conservative management of post-transplant intra-hepatic pseudo-aneurysm. 233
Prognostic Impact of Metastatic Site in Patients Receiving First-Line Sorafenib Therapy for Advanced Hepatocellular Carcinoma 228
Analysis of risk factors for tumor recurrence after liver transplantation for hepatocellular carcinoma: key role of immunosuppression. 224
EFSUMB Guidelines and Recommendations on the Clinical Use of Ultrasound Elastography.Part 2: Clinical Applications. 224
The duration of the conventional chemoembolization for hepatocellular carcinoma: factors affecting the procedural time 223
Early CTLA4 increase in CD45+ blood cells: an emerging biomarker of atezolizumab–bevacizumab resistance and worse survival in advanced hepatocarcinoma 222
Criteria for diagnosing benign portal vein thrombosis in the assessment of patients with cirrhosis and hepatocellular carcinoma for liver transplantation. 222
MiR-22/GLUT1 Axis Induces Metabolic Reprogramming and Sorafenib Resistance in Hepatocellular Carcinoma 221
Usefulness of contrast-enhanced perfusional sonography in the assessment of hepatocellular carcinoma hypervascular at spiral computed tomography. 219
Hepatocellular carcinoma recurrence in patients with curative resection or ablation: impact of HCV eradication does not depend on the use of interferon 219
Curative therapies are superior to standard of care (transarterial chemoembolization) for intermediate stage hepatocellular carcinoma. 219
Average treatment effect of hepatic resection versus locoregional therapies for hepatocellular carcinoma 218
An explorative data-analysis to support the choice between hepatic resection and radiofrequency ablation in the treatment of hepatocellular carcinoma. 215
Use of VEGFR-2 Targeted Ultrasound Contrast Agent for the Early Evaluation of Response to Sorafenib in a Mouse Model of Hepatocellular Carcinoma. 215
Nozioni di ecografia Doppler e color-Doppler 214
Reliability of imaging techniques in assessing portal venous thrombosis in patients with hepatocellular carcinoma candidates for liver transplantation 214
Affidabilità della combinazione di angioecografia perfusionale ed altre tecniche di imaging nella valutazione della trombosi portale in pazienti con epatocarcinoma (HCC) candidati al trapianto di fegato 213
Surveillance for Hepatocellular Carcinoma Also Improves Survival of Incidentally Detected Intrahepatic Cholangiocarcinoma Arisen in Liver Cirrhosis 213
Comparison between alcohol- and hepatitis C virus-related hepatocellular carcinoma: clinical presentation, treatments and outcome. 212
Comparison of International Guidelines for Noninvasive Diagnosis of Hepatocellular Carcinoma 211
Extracorporeal Detoxification for Hepatic Failure Using Molecular Adsorbent Recirculating System: Depurative Efficiency and Clinical Results in a Long-Term Follow-Up 210
The changing scenario of hepatocellular carcinoma in Italy: an update 209
Intermediate-stage hepatocellular carcinoma: refining substaging or shifting paradigm? 209
Analysis of risk factors for early hepatic artery thrombosis after liver transplantation. Possible contribution of reperfusion in the early morning. 208
Application of the Intermediate-Stage Subclassification to Patients with Untreated Hepatocellular Carcinoma 208
Correlation between LDH levels and response to sorafenib in HCC patients: an analysis of the ITA.LI.CA. database 208
CT/MRI and CEUS LI-RADS Major Features Association with Hepatocellular Carcinoma: Individual Patient Data Meta-Analysis 207
Long term follow-up and outcome of liver transplantation for alcoholic liver disease: a single center case-control study 207
Bidimensional shear wave ultrasound elastography with supersonic imaging to predict presence of oesophageal varices in cirrhosis 206
Artificial neural network is superior to MELD in predicting mortality of patients with end-stage liver disease. 205
Validation of noninvasive methods for the assessment of liver fibrosis in patients with recurrent hepatitis C after transplantation. 205
Development and Validation of a New Prognostic System for Patients with Hepatocellular Carcinoma 205
Machine Learning Predictive Model to Guide Treatment Allocation for Recurrent Hepatocellular Carcinoma After Surgery 204
Assessment of liver fibrosis in trnsplant recipients with recurrent HCV infection: Usefulness of transient elastography. 203
Direct oral anticoagulants for the treatment of splanchnic vein thrombosis: A state of art 202
Clinical and economical impact of 2010 AASLD guidelines for the diagnosis of hepatocellular carcinoma 202
Impiego clinico del “Fegato Artificiale” MARS: effetti sulle citochine e sui fattori di crescita 201
Atezolizumab plus bevacizumab as first-line treatment of unresectable hepatocellular carcinoma: interim analysis results from the phase IIIb AMETHISTA trial 200
Clinical Impact and behaviour of serum autoantibodies in adult liver transplantation 200
Metabolic disorders across hepatocellular carcinoma in Italy 200
Material deprivation affects the management and clinical outcome of hepatocellular carcinoma in a high-resource environment 200
Impact of Sarcopenia on the Survival of Patients with Hepatocellular Carcinoma Treated with Sorafenib 199
Impact of gadoxetic acid (Gd-EOB-DTPA)-enhanced magnetic resonance on the non-invasive diagnosis of small hepatocellular carcinoma: a prospective study 198
Quantification of enhancement of focal liver lesions during contrast-enhanced ultrasound (CEUS). Analysis of ten selected frames is more simple but as reliable as the analysis of the entire loop for most parameters. 197
Contrast ultrasound LI-RADS LR-5 identifies hepatocellular carcinoma in cirrhosis in a multicenter restropective study of 1,006 nodules 197
Thorough assessment of portal venous thrombosis in patients with HCC allows adequate selection of candidates for liver transplantation 197
Characteristics and survival of patients with primary biliary cholangitis and hepatocellular carcinoma 196
Assessment of donor steatosis in liver transplantation: is it possible without liver biopsy? 196
American College of Radiology Contrast Enhanced Ultrasound Liver Imaging Reporting and Data System (CEUS LI-RADS) for the diagnosis of Hepatocellular Carcinoma: A pictorial essay 196
Conditional survival after hepatic resection for hepatocellular carcinoma in cirrhotic patients. 196
HEPATIC REGENERATION WITH COUPLED PLASMAFILTRATION AND ADSORPTION FOR LIVER EXTRACORPOREAL DETOXIFICATION (HERCOLE STUDY) 195
Inter-operator variability and source of errors in tumour response assessment for hepatocellular carcinoma treated with sorafenib 195
Corrigendum to “Differences in liver stiffness values obtained with new ultrasound elastography machines and fibroscan: A comparative study” [Dig. Liver Dis. 49 (2017) 802–808](S1590865817302463)(10.1016/j.dld.2017.03.001) 194
Clinical application of artificial liver support with the Molecular Adsorbent Recirculating System (MARS): impact on cytokines and growth factors 194
Detoxification of bilirubin and bile acids with intermittent coupled plasmafiltration and adsorption in liver failure (HERCOLE study) 193
Acoustic Radiation Force Impulse elastography for fibrosis evaluation in patients with chronic hepatitis C: an international multicenter study. 192
Contrast-enhanced ultrasonography to diagnose complicated acute cholecystitis 192
An uncommon focal liver lesion: Intrahepatic splenosis 192
A benign tumour of the liver mimicking malignant liver disease--cholangiocellular adenoma. 191
Suboptimal outcomes of sorafenib as a second-line treatment after atezolizumab-bevacizumab for unresectable hepatocellular carcinoma 190
Characterization of focal liver lesions with contrast-enhanced ultrasound. 190
Patients with advanced hepatocellular carcinoma need a personalized management: A lesson from clinical practice 190
Non-invasive measurement of HVPG using graph analysis based on dynamic contrast-enhanced ultrasound with ESAOTE MyLab: The CLEVER Study. 190
Circulating CD8 lymphocytes predict response to atezolizumab–bevacizumab in hepatocellular carcinoma 189
Comparison of recurrence of hepatocellular carcinoma after resection in patients with cirrhosis to its occurrence in a surveilled cirrhotic population. 189
Trends in chronic hepatitis B virus infection in Italy over a 10-year period: Clues from the nationwide PITER and MASTER cohorts toward elimination 188
The importance of ultrasound-guided biopsy: lesson from a case of liver metastasis from uveal melanoma 188
Stadiazione epatica dei carcinomi gastrointestinali di prima diagnosi mediante angioecografia perfusionale. Confronto con TC spirale ed ecografia convenzionale. 188
Diagnostic features of real-time contrast-enhanced ultrasound in focal nodular hyperplasia of the liver. 188
Totale 22.625
Salva come PNG Salva come JPEG
Categoria #
all - tutte 200.654
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 200.654
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2020/20211.670 0 0 0 0 0 0 0 0 0 0 0 1.670
2021/20226.672 640 217 369 381 609 383 147 546 260 328 1.720 1.072
2022/20237.586 823 1.071 381 940 488 573 281 423 1.341 210 596 459
2023/20242.385 173 372 150 194 229 442 113 183 122 191 114 102
2024/202510.738 407 1.519 891 766 1.418 522 805 390 257 986 653 2.124
2025/202630.788 2.614 2.456 2.373 2.025 2.666 1.482 3.352 1.600 6.020 2.438 1.998 1.764
Totale 74.519